Coronavirus Disease 2019 Vaccine Trials (and Tribulations): How to Improve the Process of Clinical Trials in a Pandemic

Amy C Sherman; Nadine Rouphael; Lindsey R Baden

doi:10.1093/cid/ciac301

Coronavirus Disease 2019 Vaccine Trials (and Tribulations): How to Improve the Process of Clinical Trials in a Pandemic

Clin Infect Dis. 2022 Aug 15;75(Suppl 1):S5-S10. doi: 10.1093/cid/ciac301.

Authors

Amy C Sherman^{1

2}, Nadine Rouphael³, Lindsey R Baden¹

Affiliations

¹ Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
³ Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.

Abstract

Vaccine clinical trials have been essential to developing effective severe acute respiratory syndrome coronavirus 2 vaccines. The challenges of supply chain disruptions, infection control, study designs, and participant factors that affect trial procedures are reviewed, with specific solutions to streamline the clinical trial process.

Keywords: COVID-19 vaccine; clinical trials; pandemic preparedness; study design.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Pandemics* / prevention & control
SARS-CoV-2

Substances

COVID-19 Vaccines